Summary
Estrogen (ER) and progesterone receptor (PgR) positive breast tumors often respond to tamoxifen, but ultimately progress as they become tamoxifen resistant. An accurate assessment of receptor status in specimens from tamoxifen-resistant patients could help to understand potential mechanisms of resistance and to predict response to second line hormonal therapies. However, since tamoxifen itself can affect ER and PgR determinations, assay results can be misleading. We measured ER and PgR by both ligand binding (LBA) and immunohistochemical (IHC) assays in 34 tumors from patients on tamoxifen, 30 of whom were displaying resistance to the drug. These tumors were classified into several receptor phenotypes. Eleven patients, 8 of whom were clearly progressing, expressed both receptors while on tamoxifen. ER was significantly less often negative when measured by IHC, suggesting that ER status by LBA was falsely negative in this group due to receptor occupancy by tamoxifen. Six patients had no detectable ER by LBA or IHC but still expressed PgR. The presence of PgR suggests that ER could still be functional, though undetectable, in these tumors, or that PgR is constitutively expressed by them. Finally, 12 patients were ER and PgR-negative by both assays, suggesting hormonal independence as the mechanism for resistance in this group. In a subset of patients with receptor assays both prior to tamoxifen and at the time of progression while taking the drug, we found that most ER-positive tumors converted to an apparent ER-negative status when assayed by LBA, while PgR status frequently remained unchanged. The continued expression of ER and/or PgR in many patients with tumor progression on tamoxifen indicates that mechanisms for resistance other than receptor loss are common in breast cancer.
References
Buckley M, Goa KL: Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 37: 451–490, 1989
Jordan VC, Jeng MH, Jiang J, Stella AL: Hormonal strategies for breast cancer: A new focus at the estrogen receptor as therapeutic target. Semin Oncol 19: 299–307, 1992
Katzenellenbogen BS: Antiestrogen resistance: Mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy. J Natl Cancer Inst 83: 1434–1435, 1991
Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ, Metch B, Osborne CK: Prognostic significance of progesterone receptor levels in estrogen receptor positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 10: 1284–1291, 1992
Osborne CK: Receptors. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds), Breast Diseases. Second Edition. JB Lippincott Co, Philadelphia, 1991, pp 301–325
Hull DF, Clark GM, Osborne CK, Chamness GC, Knight WA III, McGuire WL: Multiple estrogen receptor assays in human breast cancer. Cancer Res 43: 413–416, 1983
Namer M, Lalane C, Baulieu E: Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer. Cancer Res 40: 1750–1752, 1980
Noguchi S, Miyauchi K, Nishizawa Y, Koyama H: Induction of progesterone receptor with tamoxifen in human breast cancer with special reference of its behavior over time. Cancer 61: 1345–1349, 1988
Waseda N, Kato Y, Imura H, Kurata M: Effects of tamoxifen of estrogen and progesterone receptor in human breast cancer. Cancer Res 41: 1984–1988, 1981
Howell A, Harland RNL, Barnes DM, Baildam AD, Wilkinson MJS, Hayward E, Swindell R: Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. Cancer Res 47: 300–304, 1987
Kiang DT, Kollander RE, Thomas T, Kennedy BJ: Up regulation of estrogen receptors by nonsteroidal antiestrogens in human breast cancer. Cancer Res 49: 5312–5316, 1989
Bezwoda R, Meyer K: Effect of α-interferon, 17β-estradiol and tamoxifen on estrogen receptor concentration and cell cycle kinetics of MCF-7 cells. Cancer Res 50: 5387–5391, 1990
Horwitz KB, Koseki Y, McGuire WL: Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 103: 1742–1751, 1978
Horwitz K, McGuire WL: Estrogen control of progesterone receptors in human breast cancer. J Biol Chem 253: 223–228, 1978
Crawford DJ, Cowan S, Fitch R, Smith DC, Leake RE: Stability of oestrogen receptor status in sequential biopsies from patients with breast cancer. Br J Cancer 56: 137–140, 1987
Nomura Y, Tashiro H, Shinozuka K: Changes of steroid hormone receptor content by chemotherapy and/or endocrine therapy in advanced breast cancer. Cancer 55: 546–551, 1985
Taylor RE, Powles TJ, Humphreys J, Bettelheim R, Dowsett M, Cassey AJ, Neville AM, Coombes RC: Effects of endocrine therapy on steroid receptor content of breast cancer. Br J Cancer 45: 80–85, 1982
McGuire WL, De La Garza M, Chamness GC: Evaluation of estrogen receptor assays in human breast cancer tissue. Cancer Res 37: 637–639, 1977
Powell B, Garola RE, Chamness GC, McGuire WL: Measurement of progesterone receptor in human breast cancer biopsies. Cancer Res 39: 1678–1682, 1979
Dressler LG, Seamer LC, Owens MA, Clark GM, McGuire WL: Flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 61: 420–427, 1988
Ciocca DR, Bjercke RJ: Immunohistochemical techniques using monoclonal antibodies. In: Langone JJ, Van Vunakis H (eds), Methods in Enzymology, Vol 121. Immunochemical Techniques. Academic Press, Miami, 1986, pp 562–579
Elias JM, Marigiotto MD: Sensitivity and detection efficiency of the peroxidase antiperoxidase (PAP), avidin-biotin peroxidase complex (ABC), and peroxidase-labeled avidin biotin (LAB) methods. Am J Clin Pathol 92: 62–67, 1989
Greene GL, Sobel MB, King WJ, Jensen EV: Immunochemical studies of estrogen receptors. J Steroid Biochem 20: 51–56, 1984
Greene GL, Harris K, Bova R, Kinders R, Moore B, Nolan C: Purification of T47D human progesterone receptor and immunochemical characterization with monoclonal antibodies. Mol Endocrinol 2: 714–726, 1988
Press MF, Greene GL: Immunocytochemical localization of estrogen and progesterone receptors. In: De Lellis RA (ed), Advances in Immunohistochemistry. Raven Press, New York, 1988, pp 341–361
Early Breast Cancer Trialists Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339: 1–15, 1992
Jensen EV, Block GE, Smith S, Kyser K, DeSombre E: Estrogen receptors and breast carcinoma response to adrenalectomy. Natl Cancer Inst Monogr 34: 55–70, 1971
McGuire WL, Carbone PP, Sears ME: Estrogen receptors in human breast cancer. An overview. In: McGuire WL, Carbone PP, Vollmer EP (eds), Estrogen Receptors in Human Breast Cancer. Raven Press, New York, 1976, pp 1–7
Rose C, Thorpe SM, Anderson KW, Pedersen BV, Mouridsen HT, Blichert-Toft M, Rasmussen BB: Beneficial effect of tamoxifen in primary breast cancer patients with high oestrogen receptor values. Lancet 1: 16–18, 1985
Glauber JG, Kiang DT: The changing role of hormonal treatment in advanced breast cancer. Semin Oncol 19: 308–316, 1992
Osborne CK, Wiebe VJ, McGuire WL, Ciocca DR, DeGregorio MW: Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen resistant tumors from breast cancer patients. J Clin Oncol 10: 304–310, 1992
Wiebe VJ, Osborne CK, McGuire WL, DeGregorio MW: Identification of estrogenic metabolite(s) in tamoxifen-resistant human breast tumors. J Clin Oncol 10: 990–994, 1992
Osborne CK, Coronado E, Allred DC, Wiebe V, DeGregorio M: Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization oftrans-4-hydroxytamoxifen. J Natl Cancer Inst 83: 1477–1482, 1991
Fuqua SAW, Fitzgerald SD, Chamness GC, Tandon AK, McDonell DP, Nawaz Z, O'Malley BW, McGuire WL: Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 51: 105–109, 1991
Gross GE, Clark GM, Chamness GC, McGuire WL: Multiple progesterone receptor assays in human breast cancer. Cancer Res 44: 836–840, 1984
Author information
Authors and Affiliations
Additional information
Deceased
Rights and permissions
About this article
Cite this article
Encarnación, C.A., Ciocca, D.R., McGuire, W.L. et al. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Tr 26, 237–246 (1993). https://doi.org/10.1007/BF00665801
Issue Date:
DOI: https://doi.org/10.1007/BF00665801